Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Good T Cells Inc.’s portfolio concerns Biotechnology & Pharmaceuticals and has 2 pending office actions. The record identifies 2 distinct examiners and 2 distinct art units, indicating that the matters are distributed across separate examination channels. Counsel should maintain independent claim and prior-art analyses while checking for opportunities to keep the biotechnology and pharmaceutical positions consistent.
REDDIG, PETER J is the busiest examiner, with 1 pending matter. The other pending action is assigned to a different examiner and art unit. This makes examiner-specific response planning important, particularly where claim scope, technical evidence, or amendment choices may need to differ between the two matters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REDDIG, PETER J | 1 | 58.0% | +40.2% |
| HINES, JANA A | 1 | 53.2% | +39.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18250209 | CELL SURFACE ANTIGEN OF ACTIVATED IMMUNE CELL AND VARIOUS USES THEREOF | HINES, JANA A | 5d |
| 18413322 | Epitope of Regulatory T Cell Surface Antigen, and Antibody Specifically Binding Thereto | REDDIG, PETER J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18250209 | CELL SURFACE ANTIGEN OF ACTIVATED IMMUNE CELL AND VARIOUS USES THEREOF | HINES, JANA A | 5d |
| 18413322 | Epitope of Regulatory T Cell Surface Antigen, and Antibody Specifically Binding Thereto | REDDIG, PETER J | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18413322 | Epitope of Regulatory T Cell Surface Antigen, and Antibody Specifically Binding Thereto | REDDIG, PETER J | 1646 | §102§112 | Non-Final OA | — | Pending | Jan 16, 2024 |
| 18250209 | CELL SURFACE ANTIGEN OF ACTIVATED IMMUNE CELL AND VARIOUS USES THEREOF | HINES, JANA A | 1645 | §102§103§112 | Final Rejection | 5d | Pending | Apr 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGood T Cells Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Peter J Reddig has the most, with 1 of Good T Cells Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
